Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Salarius Pharmaceuticals stock | $1.28
Learn how to easily invest in Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals, Inc is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 7 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Salarius Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SLRX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Salarius Pharmaceuticals stock price (NASDAQ: SLRX)Use our graph to track the performance of SLRX stocks over time.
Salarius Pharmaceuticals shares at a glance
|Latest market close||$1.28|
|52-week range||$0.63 - $3.50|
|50-day moving average||$1.00|
|200-day moving average||$1.35|
|Wall St. target price||$4.10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-176.44|
Buy Salarius Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Salarius Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Salarius Pharmaceuticals price performance over time
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||18.52%|
|3 months (2021-05-03)||-3.03%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Salarius Pharmaceuticals financials
|Revenue TTM||$5.4 million|
|Gross profit TTM||$-1,680,552|
|Return on assets TTM||-12.74%|
|Return on equity TTM||-21.33%|
|Market capitalisation||$37.7 million|
TTM: trailing 12 months
Shorting Salarius Pharmaceuticals shares
There are currently 1.5 million Salarius Pharmaceuticals shares held short by investors – that's known as Salarius Pharmaceuticals's "short interest". This figure is 19% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting Salarius Pharmaceuticals shares can be evaluated.
Salarius Pharmaceuticals's "short interest ratio" (SIR)
Salarius Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Salarius Pharmaceuticals shares currently shorted divided by the average quantity of Salarius Pharmaceuticals shares traded daily (recently around 1.2 million). Salarius Pharmaceuticals's SIR currently stands at 1.24. In other words for every 100,000 Salarius Pharmaceuticals shares traded daily on the market, roughly 1240 shares are currently held short.
However Salarius Pharmaceuticals's short interest can also be evaluated against the total number of Salarius Pharmaceuticals shares, or, against the total number of tradable Salarius Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Salarius Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Salarius Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0373% of the tradable shares (for every 100,000 tradable Salarius Pharmaceuticals shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Salarius Pharmaceuticals.
Find out more about how you can short Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals share dividends
We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.
Have Salarius Pharmaceuticals's shares ever split?
Salarius Pharmaceuticals's shares were split on a 1:25 basis on 21 July 2019. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.
Salarius Pharmaceuticals share price volatility
Over the last 12 months, Salarius Pharmaceuticals's shares have ranged in value from as little as $0.632 up to $3.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Salarius Pharmaceuticals's is 1.942. This would suggest that Salarius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Salarius Pharmaceuticals overview
Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. .
Stocks similar to Salarius Pharmaceuticals
Salarius Pharmaceuticals in the news
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow
Frequently asked questionsWhat percentage of Salarius Pharmaceuticals is owned by insiders or institutions?
Currently 1.511% of Salarius Pharmaceuticals shares are held by insiders and 39.646% by institutions. How many people work for Salarius Pharmaceuticals?
Latest data suggests 7 work at Salarius Pharmaceuticals. When does the fiscal year end for Salarius Pharmaceuticals?
Salarius Pharmaceuticals's fiscal year ends in December. Where is Salarius Pharmaceuticals based?
Salarius Pharmaceuticals's address is: 2450 Holcombe Boulevard, Houston, TX, United States, 77021 What is Salarius Pharmaceuticals's ISIN number?
Salarius Pharmaceuticals's international securities identification number is: US79400X1072 What is Salarius Pharmaceuticals's CUSIP number?
Salarius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 33938A105
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert